Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Methotrexate in inflammatory bowel disease.

Brian G Feagan1, Ahmad Alfadhli

  • 1University of Western Ontario, 100 Perth Drive, London, ON N6A 5K8, Canada. lmclellan@robarts.ca

Gastroenterology Clinics of North America
|June 5, 2004
PubMed
Summary

Methotrexate is a new treatment for Crohn's disease. Future research should combine it with biologics like infliximab for better results in therapy-resistant patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Efficacy and Safety of Etrasimod in Mildly to Moderately Active Ulcerative Colitis: Results From the Phase II GLADIATOR Trial.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026
Same author

A decade of clinical data with vedolizumab: the past, present, and future.

Therapeutic advances in gastroenterology·2026
Same author

Pre-Crohn's Disease Stool From Discordant Siblings Promotes the Development of Colitis in Germ-Free Mice.

Gastroenterology·2026
Same author

Evaluating treatment to a target of transmural healing in patients with moderately to severely active Crohn's disease: rationale, design and protocol for the randomised controlled VECTORS trial.

BMJ open gastroenterology·2026
Same author

Association between endo-histological outcomes and colonic mucosal transcriptomic profiles in patients with ulcerative colitis receiving filgotinib.

Journal of Crohn's & colitis·2026
Same author

Design and rationale for the VICTRIVA study: A randomized, double-blind, phase 3b study of vedolizumab in combination with upadacitinib in Crohn's disease.

Contemporary clinical trials communications·2025

Area of Science:

  • Gastroenterology
  • Immunology
  • Pharmacology

Background:

  • Methotrexate has become a significant treatment option for chronic Crohn's disease over the last decade.
  • Azathioprine and methotrexate are established treatments for Crohn's disease, but direct comparative trials in therapy-resistant populations are challenging.
  • The need for effective therapies for refractory Crohn's disease persists.

Purpose of the Study:

  • To discuss the role of methotrexate in managing chronically active Crohn's disease.
  • To evaluate the feasibility of conducting comparative trials between azathioprine and methotrexate in therapy-resistant patients.
  • To suggest future research directions for optimizing treatment strategies in Crohn's disease.

Main Methods:

  • Literature review on methotrexate and azathioprine in Crohn's disease.
  • Analysis of the challenges in designing comparative efficacy and safety trials for these agents.
  • Exploration of potential combination therapies.

Main Results:

  • Methotrexate is an emerging treatment for active Crohn's disease.
  • Direct comparative trials between azathioprine and methotrexate in therapy-resistant patients are likely unfeasible due to minimal differences in potency and tolerability.
  • Combination therapy with biologics shows promise.

Conclusions:

  • Methotrexate is a valuable option for Crohn's disease management.
  • Future research should focus on combination therapies, particularly with biologics like infliximab, for patients with refractory disease.
  • Investigating synergistic effects of methotrexate with biologic agents is a key area for advancing Crohn's disease treatment.

Related Experiment Videos